{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 109,
  "pageCount": 132,
  "prevPage": 108,
  "nextPage": 110,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/109",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-109",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.385
      },
      "kind": "list",
      "text": "Demonstrate that tumor-targeted IL-12 subunits are retained in tumors with expected kinetics",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fd2c94c-18a7-4eef-9409-53cada9bad1f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.58
      },
      "kind": "list",
      "text": "Complete humanization of tumor-targeting antibodies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "49ae49e6-064e-4192-92d7-a8ae82977916",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.78
      },
      "kind": "list",
      "text": "Initiate cell line development",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6f5d17c2-63fc-46fb-9d55-a69fa6004de5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.275
      },
      "kind": "list",
      "text": "Engineer tumor-targeted IL-12 subunits (fused to proprietary tumor-targeting antibody)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7aa604f8-5303-4b44-b2c4-1d7df32e713f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "list",
      "text": "Characterize lead candidates and preclinical proof-of-concept studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7bc55a37-5d2c-414f-a348-314909192287",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.48
      },
      "kind": "list",
      "text": "Demonstrate that sequentially-administered IL-12 subunits combine to form functional IL-12 and drive dose-dependent IFN-y production in humanized mice",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc8718dc-1709-49fd-898a-39d5e0624517",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Tumor-Targeted Split IL-12: Advancing Toward Preclinical Proof-of-Concept and Cell Line Development",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d047d74-f415-4fe4-8375-bdfd7bd8b6f0",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}